Multidrug resistance in AIDS-related lymphoma

Current Opinion in Oncology

Volumn 17, Issue 5, 2005, Pages 466-468

  Tulpule, Anil ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

AIDS related lymphoma; Multidrug resistance; P glycoprotein

Indexed keywords

AMIODARONE; ANTISENSE OLIGODEOXYNUCLEOTIDE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOXORUBICIN; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; PREDNISONE; QUINIDINE; RECOMBINANT RNA; SMALL INTERFERING RNA; TAMOXIFEN; VALSPODAR; VERAPAMIL; VINCRISTINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANCER COMBINATION CHEMOTHERAPY; CHEMOSENSITIVITY; DISEASE ASSOCIATION; DRUG RESPONSE; GENE OVEREXPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LYMPHOMA; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; TREATMENT OUTCOME;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE, VIRAL; GENE EXPRESSION REGULATION, VIRAL; GENES, MDR; HUMANS; LIPOSOMES; LYMPHOMA, AIDS-RELATED; P-GLYCOPROTEIN; PREDNISONE; PROGNOSIS; VINCRISTINE;

EID: 24044470370     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000172825.85942.d6     Document Type: Review

References (23)

1. Dano K. Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim Biophys Acta 1973; 323:466-483.
2. Kartner N, Riordan JR, Ling V. Cell surface P-glycoprotein associated with multi drug resistance in mammalian cell lines. Science 1983; 221:1285-1288.
3. Ueda K, Coswell MM, Gottesman MM, et al. The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein. Biochem Biophys Res Commun 1986; 141:956-962.
4. Miller TP, Grojan TM, Dalton WS, et al. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 1991; 17-24.
5. Goldstein LJ, Galski H, Fojo A, et al. Expression of a human multidrug resistance gene in human cancers. J Natl Cancer Inst 1989; 81:116-124.
6. Cheng A-L, Su I-J, Chen Y-C, et al. Expression of P-glycoprotein and glutathione-S-transferase in recurrent lymphomas: the possible role of Epstein-Barr virus, immunophenotypes and other predisposing factors. J Clin Oncol 1993; 11: 109-115.
7. Rodriguez C, Commes T, Robert J, Rossi JF. Expression of P-glycoprotein and anionic glutathione S-transferase genes in non-Hodgkin's lymphoma. Leuk Res 1993; 17:149-156.
8. Pileri S, Sabattini E, Falini, et al. Immunohistochemical detection of the multidrug transport protein P170 in human normal tissues and malignant lymphomas. Histopathology 1991; 19:131-140.
9. Levine AM, Seneviratne L, Espina BM, et al. Evolving characteristics of AIDS-related lymphoma. Blood 2000; 96:4084-4090.
10. Lim ST, Karim R, Nathwani BN, et al. AIDS-related Burkitt's lymphoma (HIV-BL) versus diffuse large cell lymphoma (HIV-DLCL) in the pre HAART and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol 2005; May 9; [Epub ahead of print.] Describes the differences in histology and clinical outcomes in AIDS-*related NHL in the eras before and after the introduction of highly active antiretroviral therapies.
11. Straus DJ. Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma. Recent Results Cancer Res 2002; 159:143-148.
12. Robotin MC, Law MG, Milliken S, et al. Clinical features and predictors of survival of AIDS-related non-Hodgkin's lymphoma in a population-based case series in Sydney, Australia. HIV Med 2004; 5:377-384.
13. Wolf T, Brodt HR, Fichtlscherer S, et al. Changing incidence and prognostic factors of survival in AIDS-related non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy (HAART). Leuk Lymphoma 2005; 46: 207-215.
14. Tulpule A, Sherrod A, Dharmapala D, et al. Multidrug resistance (MDR-1) expression in AIDS-related lymphomas. Leuk Res 2002; 26:121-127.
15. Fisher GA, Sikic BI. Clinical studies with modulators of multidrug resistance. Hematol Oncol Clin North Am 1995; 9:363-382.
16. Saponara S, Kawase M, Shah A, et al. 3,5-Dibenzoyl-4-(3-phenoxyphenyl)-1, 4-dihydro-2,6-dimethylpyridine (DP7) as a new multidrug resistance reverting agent devoid of effects on vascular smooth muscle contractility. Br J Pharmacol 2004; 141:415-422.
17. Xu D, Kang H, Fisher M, Juliano RL. Strategies for inhibition of MDR-1 gene expression. Mol Pharmacol 2004; 66:268-275.
18. Kang H, Fisher M, Xu D, et al. Inhibition of MDR-1 gene expression by chimeric HNA antisense oligonucleotides. Nucleic Acids Res 2004; 32:4411-4419.
19. Rittierodt M, Tschernig T, Harada K. Modulation of multidrug resistance associated P-glycoprotein in human U-87 and HUV-ECC cells with antisense oligonucleotides to MDR-1 mRNA. Pathobiology 2004; 71:123-128.
20. Rahman A, Husain Sr, Siddiqui J, et al. Liposome mediated modulation of multidrug resistance in human HL-60 leukemia cells. J Natl Cancer Inst 1992; 84: 1909-1915.
21. Thierry AR, Vige D, Coughlin SS, et al. Modulation of doxorubicin resistance in multidrug-resistant cells by liposomes. FASEB J 1993; 7:572-579.
22. Fan D, Bucana CD, O'Brian C, et al. Enhancement of murine tumor cell sensitivity to adriamycin by presentation of the drug in phosphatidylcholine- phosphatidylserine liposomes. Cancer Res 1990; 50:3619-3626.
23. Levine AM, Tulpule A, Espina B, et al. Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response. J Clin Oncol 2004; 22:2662-2670. Study providing evidence that liposomal encapsulation of doxorubicin can overcome MDR-1-mediated drug resistance in vivo.